Editors' Picks  by unknown
EDITORS' PICKS
2482 Journal of Investigative Dermatology (2014), Volume 134 © 2014 The Society for Investigative Dermatology
Common strategies
Owing to the limited efficacy of treatments for moderate to 
severe atopic dermatitis (AD), which affects 20% of patients 
with this common disease, development of novel treatment 
strategies is of the utmost importance. Recently, a clinical study 
of dupilumab—a fully human monoclonal antibody that tar-
gets the shared α-subunit of the IL-4 receptors to block both 
IL-4 and IL-13—reported efficacy in patients with moderate to 
severe asthma. To test the effects of this drug in other diseases 
characterized by T helper type 2 cytokine pathogenesis, Beck 
and colleagues evaluated dupilumab in four randomized, 
double-blind, placebo-controlled trials of adults with moder-
ate to severe AD. In all these studies, dupilumab treatment as 
monotherapy or in combination with glucocorticosteroids was 
associated with marked improvement in skin lesions and reduc-
tions in pruritus as well as reductions in all assayed biomarker 
levels and improvement of the lesional transcriptome of AD. 
Interestingly, adverse events were more common in the pla-
cebo control groups. These results support the use of this new 
biologic therapy in a second atopic disorder and highlight the 
potential commonality of related allergic drivers. (N Engl J Med 
371:130–9, 2014) Selected by E. Lerner
Animals on parade
In a recent analysis of whether animal research is sufficiently 
evidence-based to be a cornerstone of biomedical research, 
Pound and Bracken highlighted the challenges of translating 
animal studies to clinical medicine. Because the conduct, 
reporting, and synthesis of a considerable number of animal 
research studies remain inadequate, these researchers found 
that many of the analyzed studies failed to address threats to 
internal and external validity, rendering the applicability of 
the results to clinical medicine questionable. Indeed, less than 
10% of promising basic-science discoveries are translated to 
clinical practice within 20 years. Especially problematic is the 
exposure of humans to potentially dangerous drugs as a result 
of tenuous animal studies. Overall, this analysis champions an 
improved systematic review effort, training in experimental 
design, adherence to higher standards of research conduct and 
reporting, prospective registration of preclinical reporting, and 
dissemination of both positive and negative findings to ensure 
the best allocation of public research dollars. (BMJ 348:g3387, 
2014) Selected by H. Williams
Follow the environmental signals
Although 36 disease-associated loci have been identified as 
contributing to psoriasis, environmental factors, which are 
known to be involved in its pathogenesis, remain largely unde-
fined. To investigate the potential influence of environmental 
factors on inflammatory skin diseases, Di Meglio and colleagues 
examined the aryl hydrocarbon receptor (AhR), a transcription 
factor that mediates environmental stimuli signaling, in skin 
biopsy specimens from psoriasis patients and a mouse model 
of psoriasiform inflammation induced via imiquimod treatment. 
Environmental signals transmitted via the AhR dampen the 
inflammatory response. In both mice and humans, disruption of 
the AhR gene results in hyperinflammation, whereas activation 
of the AhR ameliorates the inflammatory response. Interestingly, 
current psoriasis treatment strategies target inflammatory 
immune parameters; however, these study findings indicate 
that the response of nonhematopoietic skin cells to inflamma-
tory stimuli via AhR are important for skin homeostasis, open-
ing up a new avenue for future therapeutic discovery. (Immunity 
40:989–1001, 2014) Selected by N. Ward and T. Schwarz
Shedding light on addiction
Although UVR is a known risk factor for cutaneous malignan-
cies, some studies suggest that sun-seeking behavior results 
from endogenous opioid-mediated addictive behavioral activ-
ity. Fell and colleagues recently found that UVR exposure pro-
duces an opioid receptor–mediated addiction via increased 
circulating β-endorphin. The increased levels of this common 
endogenous opioid, which is known to cause analgesia, were 
associated with increased nociceptive thresholds. Treatment 
of the mice exposed to chronic UVR with the opioid antago-
nist naloxone resulted in withdrawal symptoms. In addition, 
β-endorphin knockout animals lacked these nociceptive and 
behavioral effects. Furthermore, p53, which performs a critical 
role in the UV-response pathway, appeared to be involved in 
the β-endorphin elevation and behavioral responses. These find-
ings, which should be further investigated in the context of sun-
screen, suggest that recreational tanning and opioid drug abuse 
involve the same biological pathway. (Cell 157:1527–34, 2014) 
Selected by B. Gilchrest
Sunscreen benefits for melanoma
UVR is known to be linked to melanomagenesis, although the 
underlying mechanisms are not clear. Viros and colleagues 
recently identified the tumor suppressor TP53 as a lynchpin in 
the UVR-induced melanoma pathway. Using mice harboring 
the BRAF(V600E) mutation, which occurs somatically as an 
early event in a majority of melanomas in acquired human nevi, 
these investigators found that sunscreen delayed the onset of 
melanoma following UVR exposure but provided only partial 
protection. In these mice, the Trp53 gene exhibited mutations 
in 40% of cases. Mutant TP53 accelerated BRAF(V600E)-
driven melanoma in mice, and mutations in TP53 were found 
to be associated with UVR-induced DNA damage in humans. 
Together, these findings implicate TP53 as a UVR target and crit-
ical player in melanomagenesis. Clinically, the results support 
the use of sunscreen protection for patients at risk of melanoma. 
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